drugset
drugset / Trial / NCT05525468

A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects

NCT05525468 ↗

Phase 1 Completed 58 enrolled Technoderma Medicines Inc. Therapeutics, Inc. · collab
RandomizedSequentialDouble-blindTreatment

Summary

Multi-center, randomized, double-blind, vehicle-controlled, parallel group, dose escalation study of TDM-180935 following topical administration in healthy male subjects, 18 to 55 years old

Timeline

Start
2023-02-08
Primary completion
2023-08-18
Completion
2023-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject TDM-180935 Unknown 0.25 % Topical
Subject TDM-180935 Unknown 0.5 % Topical
Subject TDM-180935 Unknown 1 % Topical
Subject TDM-180935 Unknown 2 % Topical

Indications

No indication recorded.